Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 495-502

  Gantt, Soren ^a,b,c   Casper, Corey ^a,c,d   Ambinder, Richard F ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Fred Hutchinson Cancer Research Center   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; HIV protease inhibitor; Kaposi sarcoma; Nelfinavir; Treatment

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AMPRENAVIR; ATAZANAVIR; CISPLATIN; GEMCITABINE; GLUCOSE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEIN KINASE B; RAPAMYCIN; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BLADDER CARCINOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL INVASION; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG USE; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; EPSTEIN BARR VIRUS; FIBROSARCOMA; GLIOBLASTOMA; GLIOMA; GLUCOSE BLOOD LEVEL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHYSIS ADENOMA; INCIDENCE; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MORTALITY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NEOPLASM; NEUROBLASTOMA; OVARY CANCER; PANCREATITIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; ROSEOLOVIRUS; SIDE EFFECT; SKIN TOXICITY; T CELL LEUKEMIA; T CELL LYMPHOMA; TRIACYLGLYCEROL BLOOD LEVEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); NEOPLASMS;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84883225852     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328363dfee     Document Type: Review

References (80)

1. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 2008; 3: 666-675.
2. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009; 10: 61-71.
3. Agouron Pharmaceuticals I. Viracept package insert. 2009. http://www. accessdata.fda.gov/drugsatfda-docs/label/2005/021503s006lbl.pdf
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.- gov/ContentFiles/AdultandAdolescentGL.pdf
5. Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 1997; 11: 1653-1655.
6. Burdick AE, Carmichael C, Rady PL, et al. Resolution of Kaposi's sarcoma associated with undetectable level of humanherpesvirus8DNAin a patient with AIDSafter protease inhibitor therapy. JAmAcad Dermatol 1997; 37: 648-649.
7. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997; 11: 1300-1301.
8. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11: 261-262.
9. Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, et al. Regression of AIDSrelated Kaposi's sarcoma following ritonavir therapy. Oral Oncol 1998; 34: 236-238.
10. Jung C, Bogner JR, Goebel F. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 1998; 3: 439-442.
11. Krischer J, Rutschmann O, Hirschel B, et al. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 1998; 38: 594-598.
12. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12:F45-F49.
13. De Milito A, Catucci M, Venturi G, et al. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8- coinfected patients. J Med Virol 1999; 57: 140-144.
14. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on kaposi sarcoma-associated herpesvirus infection in patients with and without kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31: 384-390.
15. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94: 1000-1006.
16. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009; 23: 1701-1706.
17. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22.
18. Grabar S, Abraham B, Mahamat A, et al. Differential impact of combination antiretroviral therapy in preventing kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24: 3408-3414.
19. Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009; 51: 305-309.
20. Gupta AK, Cerniglia GJ, Mick R, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65: 8256-8265.
21. Yang Y, Ikezoe T, Takeuchi T, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005; 96: 425-433.
22. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13: 5183-5194.
23. Zeng J, See AP, Aziz K, et al. Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther 2011; 12: 657-663.
24. Bono C, Karlin L, Harel S, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiplemyelomacellsin vitroandin vivo.Haematologica2012;97: 1101-1109.
25. Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013; 3:e103. A careful study showing that in multiple myeloma cells, nelfinavir had the greatest cytotoxic activity among the protease inhibitors, and displayed synergy with bortezomib/carfilzomib even in bortezomib/carfilzomib-resistant cells. This effect appeared to be due to nelfinavir's greater activity on the proteasome inhibition of ER stress, rather than Akt inhibition, which was comparable among all nine protease inhibitors tested.
26. Yang Y, Ikezoe T, Nishioka C, et al. NFV an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer 2006; 95: 1653-1662.
27. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxiainducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006; 66: 9252-9259.
28. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversedbythe proteaseinhibitor nelfinavir.CancerRes2007; 67: 4467-4473.
29. Shim JS, Rao R, Beebe K, et al. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst 2012; 104: 1576-1590. A detailed study describing the selective growth inhibiton of Her2-positive breast cancer cells by nelfinavir in vitro, and evidence that nelfinavir acts on HSP90, rather than the proteasome.
30. Petrich AM, Leshchenko V, Kuo PY, et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2012; 18: 2534-2544. A panel of DLBCL cell lines was studied using pathway analysis and connectivity mapping, which identified Akt as central to the rapamycin resistance. Nelfinavir and MK-2206, both inhibitors of Akt, were synergistic with rapamycin in killling DLBCL cell lines.
31. Gupta AK, Li B, Cerniglia GJ, et al. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007; 9: 271-278.
32. Sato A, Asano T, Ito K. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells. Urology 2012; 79: 966; e913-e921.
33. Bruning A, Vogel M, Mylonas I, et al. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 2011; 11: 799-809.
34. Tian X, Ye J, Alonso-Basanta M, et al. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286: 29408-29416.
35. Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007; 67: 10920-10928.
36. Bruning A, Burger P, Vogel M, et al. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol Ther 2009; 8.
37. Bruning A. Analysis of nelfinavir-induced endoplasmic reticulum stress. Methods Enzymol 2011; 491: 127-142.
38. Guan M, Fousek K, Jiang C, et al. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res 2011; 17: 1796-1806.
39. Kawabata S, Gills JJ, Mercado-Matos JR, et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012; 3:e353.
40. Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anticancer drug with pleiotropic effects and many paths to autophagy. Autophagy 2008; 4: 107-109.
41. Thomas S, Sharma N, Golden EB, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer lett 2012; 325: 63-71.
42. Mahoney E, Maddocks K, Flynn J, et al. Identification of endoplasmic reticulum stress inducing agents by antagonizing autophagy: A new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. Leuk Lymphoma 2013.
43. Guan M, Fousek K, Chow WA. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. FEBS J 2012; 279: 2399-2411.
44. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99: 3771-3779.
45. Sun L, Niu L, Zhu X, et al. Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells. J Chemother 2012; 24: 161-166.
46. Dewan MZ, Uchihara JN, Terashima K, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006; 107: 716-724.
47. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6- dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11: 813-825.
48. Jiang W, Mikochik PJ, Ra JH, et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007; 67: 1221-1227.
49. Dewan MZ, Tomita M, Katano H, et al. An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer 2009; 124: 622-629.
50. Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62: 5230-5235.
51. Srirangam A, Milani M, Mitra R, et al. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol 2011; 6: 661-670.
52. Timeus F, Crescenzio N, Doria A, et al. In vitro antineuroblastoma activity of saquinavir and its association with imatinib. Oncol Rep 2012; 27: 734-740. A study demonstrating that saquinavir has a dose-dependent antiproliferative and antiinvasive activity on NB lines, that was potentiated by imatinib, with both at clinically attainable concentrations. These effects appeared to be due to inhibition of NF-kappaB and possibly induction of apoptosis.
53. Srirangam A, Mitra R, Wang M, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res 2006; 12: 1883-1896.
54. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62: 6901-6908.
55. Barillari G, Iovane A, Bacigalupo I, et al. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. AIDS 2012; 26: 909-919.
56. Esposito V, Verdina A, Manente L, et al. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol 2013; 228: 640-645.
57. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225-232.
58. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998; 95: 13120-13124.
59. Xie L, Evangelidis T, Bourne PE. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anticancer effect of nelfinavir. PLoS Comput Biol 2011; 7:e1002037.
60. Lucia MB, Anu R, Handley M, et al. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. Brit J Cancer 2011; 105: 513-522.
61. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 2006; 8: 889-895.
62. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 121-130.
63. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 71: 829-842.
64. Plastaras JP, Vapiwala N, Ahmed MS, et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008; 7: 628-635.
65. Schonthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 2013; 85: 653-666.
66. Martinon F. Targeting endoplasmic reticulum signaling pathways in cancer. Acta oncologica 2012; 51: 822-830.
67. Chow WA, Guo S, Valdes-Albini F. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs 2006; 17: 891-903.
68. Kraus M, Malenke E, Gogel J, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008; 7: 1940-1948.
69. Shirley C, Kalu N, Shamay M, Ambinder RF. Epstein-Barr virus lytic gene expression is tightly linked to ER stress but not cytotoxicity with bortezomib or nelfinavir. In International Congress on Oncogenic Herpesviruses and Associated Diseases, Philadelphia, PA. Infect Agent Cancer 2012; 7 (Suppl 1): 32.
70. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013; 368: 651-662.
71. Weichold FF, Bryant JL, Pati S, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol 1999; 2: 261-269.
72. Gantt S, Carlsson J, Ikoma M, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011; 55: 2696-2703.
73. Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24: 295-301.
74. Kalu N, Shirley C, Ambinder RF. ER stress activates lytic gene expression in KSHV associated tumor cell lines. In International Congress on Oncogenic Herpesviruses and Associated Diseases, Philadelphia, PA. Infect Agent Cancer 2012; 7 (Suppl 1):P33.
75. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120: 939-949.
76. Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009; 23: 534-538.
77. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26: 2699-2706.
78. Rengan R, Mick R, Pryma D, et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB nonsmall cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012; 7: 709-715. Nelfinavir was given in combination with cisplatin, etoposide, and radiation. There appeared to be no toxicities that were attributable to nelfinavir, suggesting that a dose of 1250mg BID with concurrent radiation chemotherapy was appropriate for further study.
79. Dennis P, Blumenthal G, Ballas M, et al. A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. In J Clin Oncol (Meeting Abstracts) 2009; 2583.
80. Pan J, Mott M, Xi B, et al. Phase I study of nelfinavir in liposarcoma. Cancer Chemother Pharmacol 2012; 70: 791-799. This is a dose-escalation study of nelfinavir for liposarcoma. No dose-limited toxicities were observed. Pharmacokinetic analyses suggest that there may be only minimal increases in plasma drug concentrations with nelfinavir doses above 1875mg BID, and that the drug induces its own clearance at doses of 4500mg BID.